BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

KYTHERA Biopharmaceuticals, Inc. 

30930 Russell Ranch Road

Westlake Village  California  91362  U.S.A.
Phone: 818-587-4500 Fax: 818-587-4591


SEARCH JOBS



KYTHERA is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Our objective is to develop first-in-class, prescription products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. Our initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. KYTHERA’s product candidate, ATX-101, is currently in late-stage clinical development for the reduction of submental fat, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. KYTHERA submitted its New Drug Application for ATX-101 in May 2014, which the FDA has determined will be subject to a standard review and will have a Prescription Drug User Fee Act (PDUFA) action date of May 13, 2015. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.

OUR FOUNDING: KYTHERA Biopharmaceuticals was founded in 2005 on the premise on building a new kind of biotechnology company – one aimed squarely at bringing great science, clinical rigor and real innovation to the growing area of aesthetic medicine.


OUR INSPIRATION: KYTHERA Biopharmaceuticals, Inc. is named after an island off the coast of southern Greece, in the Mediterranean Sea. Southernmost of the Ionian Islands, the island of Kythera was the chief center for the worship of Aphrodite, the Greek goddess of beauty and love. Our colors symbolize sky blue and sand.

OUR MANAGEMENT TEAM: We have a highly experienced management team, many of whom have played a leadership role in securing FDA approval of marquee aesthetic products, such as BOTOX® and JUVEDERM®, and in successfully commercializing established biotechnology products such as Aranesp®, NEUPOGEN® and Neulasta®.




 Key Statistics


Email:
Ownership: Public

Web Site: KYTHERA Biopharmaceuticals, Inc.
Employees:
Symbol: KYTH
 









 Company News
KYTHERA Biopharmaceuticals, Inc. (KYTH) Grants Stock Options Under Inducement Program 12/15/2014 8:03:01 AM
KYTHERA Biopharmaceuticals, Inc. (KYTH) To Present At The Goldman, Sachs & Co. US Emerging / SMID Cap Growth Conference 11/17/2014 2:15:43 PM
Kythera Biopharmaceuticals (KYTH) Releases Third Quarter 2014 Operating Results 11/11/2014 8:04:24 AM
Kythera Biopharmaceuticals (KYTH) Grants Stock Options Under Inducement Program 11/5/2014 7:18:49 AM
Kythera Biopharmaceuticals (KYTH) To Release Third Quarter 2014 Operating Results 11/4/2014 7:53:43 AM
Kythera Biopharmaceuticals (KYTH) Grants Stock Options Under Inducement Program 10/22/2014 7:08:50 AM
Kythera Biopharmaceuticals (KYTH) Grants Stock Options Under Inducement Program 10/13/2014 7:44:26 AM
Kythera Biopharmaceuticals (KYTH) Submits New Drug Submission To Health Canada For ATX-101 As First-In-Class Treatment For The Reduction Of Submental Fat 8/11/2014 5:24:44 PM
Kythera Biopharmaceuticals (KYTH) Releases Second Quarter 2014 Operating Results 8/8/2014 10:41:33 AM
Kythera Biopharmaceuticals (KYTH) To Release Second Quarter 2014 Operating Results 8/1/2014 9:09:44 AM
12345678910